Project

General

Profile

Wiki » History » Version 50

Jason Bobe, 03/02/2010 02:29 PM
language correction

1 36 Jason Bobe
 = Genotype + Environment = Trait Evidence (GET-E) Database = 
2 1 Jason Bobe
3 38 Jason Bobe
The '''GET-E''' project was started by Abraham Rosenbaum, Joe Thakuria, Xiaodi Wu and Alexander Wait Zaranek to help the [http://personalgenomes.org Personal Genome Project], the clinical genetics community, and, the general public interpret individual genomes.  The database is closely integrated with [wiki:Trait-o-matic].
4 1 Jason Bobe
5
You can find the PGP production server at:
6
 * http://evidence.personalgenomes.org
7
8
A development sandbox can be found at: 
9
 * http://evidence-dev.personalgenomes.org
10
11 37 Jason Bobe
Many contributors helped make '''GET-E''' possible. You can find specific contributions at: 
12 1 Jason Bobe
 * http://evidence.personalgenomes.org/editors
13
14 38 Jason Bobe
Please help the project by editing the database, writing software tools that use the database (eg. Trait-o-matic/AETAS) or by making suggestions on the wiki!  
15 1 Jason Bobe
16 28 Jason Bobe
 == Field Descriptions and Editing Guidelines ==
17 19 Jason Bobe
 === Short Summary === 
18
 * free text providing a one line summary of clinical action to be undertaken given this variant (possibly modified by known phenotypes). 
19
20 23 Jason Bobe
 === Variant Quality Data === 
21 1 Jason Bobe
Each of these fields is a sliding scale of 0-5 where 0 represents no evidence and 5 strong evidence that the Impact is correct. Where the data is not entered the default is N/A. When Genetests and/or the literature correlate this variant with a number of phenotypes the impact should be reported for the most extreme condition
22 35 Jason Bobe
 a. ''In silico'': One star for each consistent prediction and one star subtracted for conflicting results from:
23 26 Jason Bobe
  i. evolutionary conservation (minimum of three species)
24
  i. presence in active domain 
25 27 Jason Bobe
  i. SIFT 
26
  i. !PolyPhen 
27 44 Jason Bobe
  i. NBLOSUM >= 2
28 27 Jason Bobe
  i. GVGD
29 23 Jason Bobe
  i. Other variants in this gene cause similar disease 
30
  i. etc... 
31
 a. ''In vitro'': One star for each experiment supporting the result, and penalize one star for conflicting results from: 
32
  i. enzyme extracts 
33
  i. cell lines  
34
  i. animal models
35
  i. etc... 
36 50 Jason Bobe
 a. Case/Control: A combination of odds ratio and significance test (currently using Fisher's Exact Test). For protective alleles, use inverse OR = 1 / OR. Do not count related individuals, count probands -- ie. one per family
37 40 Jason Bobe
  i. 0 stars if no higher ranking is allowed
38 41 Jason Bobe
  i. 1 star if OR>1 and significance <= 0.1
39
  i. 2 stars if OR>=1.5 and significance <= 0.05
40 45 Jason Bobe
  i. 3 stars if OR>=2 and significance <= 0.025
41
  i. 4 stars if OR>=3 and significance <= 0.01
42
  i. 5 stars if OR>=5 and significance <= 0.0001
43 24 Jason Bobe
 a. Familial Disease Segregation
44 25 Jason Bobe
  i. 0 stars for no segregation (LOD < -2)
45 24 Jason Bobe
  i. 1 star if segregation exists in one family pedigree
46
  i. 2 stars for segregation in more than one family with some conflicting information (e.g. asymptomatic carrier of young age or possibility of second causative mutation)
47
  i. 3 stars for more than one family no conflicting information
48
  i. 4 stars for LOD > 2
49 46 Jason Bobe
  i. 5 stars for LOD > 3
50 1 Jason Bobe
 a. Clinical Outcomes: The quality of studies investigating the effectiveness of action based on the described impact of this mutation given a specific phenotype/family history
51 46 Jason Bobe
  i. 0 stars for negative outcome for intervention (diagnostic and medical)
52 25 Jason Bobe
  i. 1 star no proven benefit for intervention
53 47 Jason Bobe
  i. 2 stars if intervention is in development or evidence is anecdotal 
54
  i. 3 conflicting evidence for intervention
55
  i. 4 established intervention (eg. familial mediterranean fever)
56
  i. 5 established intervention: lethal or severe disease in the absence of intervention (eg. familial adenomatous polyposis)
57
58 19 Jason Bobe
 === Impact === 
59 32 Jason Bobe
 a. Pathogenic: Causative for disease. 
60
 a. Benign: No clinically significant phenotype. 
61 1 Jason Bobe
 a. Protective: Protective from disease.
62
 a. Pharmacogenetic: Clinically significant phenotype in the presence of a pharmacological agent.    
63 43 Jason Bobe
 a. NR: Not reviewed.
64 34 Jason Bobe
65 48 Jason Bobe
In addition to these impacts, qualifiers will be added according to the variant quality information (ie. the stars). "Clinical outcome" score is treated as no higher than the maximum score of either "case/control" or "familial". The evidence must have at least four stars in any one of the clinical categories (case/control, familial, clinical outcomes) and at least ten stars total from all categories for the impact to be unqualified (ie. "pathogenic", "benign", "protective", or "pharmacogenetic").  The evidence must have three stars in any one of the clinical categories and at least six stars total from all categories for the impact to be qualified as "likely" (ie. "likely pathogenic", etc). All other impacts are qualified as "uncertain" (ie. "uncertain pathogenic", etc).
66 39 Jason Bobe
67
When Genetests and/or the literature give multiple phenotypes for a variant, the impact should be reported for the most extreme condition and annotated as such in the ''short summary''. In the future we hope to list different phenotypes separately.
68 19 Jason Bobe
69
 === Inheritance Pattern === 
70
 a. Dominant
71
 a. Recessive
72
 a. Other: A defined form of inheritance that is neither dominant or recessive (e.g. modifier, co-dominant, incomplete penetrance). These variants will get prioritized due to their potential phenotypic affect should the additional factors be present.
73
 a. Undefined: Undefined in the literature.
74
 a. Unknown: The default value for all variants and all variants without literature.
75
76
 === Summary of published research, and additional commentary === 
77 22 Jason Bobe
 * Free text providing a comprehensive review of the variant including youngest age of onset, oldest age of onset and oldest asymptomatic individual. 
78 1 Jason Bobe
79 21 Jason Bobe
 === Allele Frequency === 
80 22 Jason Bobe
 * Automatically generated frequencies for the !HapMap Project, 1000 Genomes Project and the weighted average of the two.  Sub-population frequencies and homozygous/heterozygous break-downs are currently not shown. 
81 21 Jason Bobe
82
 === Publications === 
83
84
 * User-entered publications and user entered synopses of the relevant details from the publication. A short summary is also entered for each paper (as above).
85
 
86
 === Genomes ===  
87
88
 * Automatically generated list of all genomes from Trait-o-matic in which this variant is seen. Additionally, specific actions taken by each individual harboring the variant can be reported.
89
 
90
 === Other External References === 
91
These are automatically generated by web "robots":  
92 13 Jason Bobe
   a. dbSNP: The link to the dbSNP entry for this nucleotide position (for this nucleotide change?)
93 12 Jason Bobe
   a. Genetests: Link to all clinical laboratories performing diagnostic tests on this gene and the list of diseases that the labs are looking for.
94
   a. Web Search Results: A web search for this exact variant using the Yahoo search engine
95 21 Jason Bobe
96
 === Edit History ===
97
 * Automatically generated history of all page edits with the contributor's name.
98 20 Jason Bobe
99
 == To Do ==
100
 * [wiki:GET-Evidence/23andWe]
101 3 Jason Bobe
102 1 Jason Bobe
 == Suggestions == 
103
104
 * your suggestion here.